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ABSTRACT:
The PI3K/AKT pathway governs a plethora of cellular processes, including cell 
growth, proliferation, and metabolism, in response to growth factors and cytokines. 
By acting as a unique lipid phosphatase converting phosphatidylinositol-3,4,5,-
trisphosphate (PIP3) to phosphatidylinositol-4,5,-bisphosphate (PIP2), phosphatase 
and tensin homolog (PTEN) acts as the major cellular suppressor of PI3K signaling 
and AKT activation. Recently, PI3K mutations and loss/mutation of PTEN have been 
characterized in human gallbladder tumors; whether aberrant PTEN/PI3K pathway 
plays a causal role in gallbladder carcinogenesis, however, remains unknown. Herein 
we show that in mice, deregulation of PI3K/AKT signaling is sufficient to transform 
gallbladder epithelial cells and trigger fully penetrant, highly proliferative gallbladder 
tumors characterized by high levels of phospho-AKT. Histopathologically, these 
mouse tumors faithfully resemble human adenomatous gallbladder lesions. The 
identification of PI3K pathway deregulation as both an early event in the neoplastic 
transformation of the gallbladder epithelium and a main mechanism of tumor growth 
in Pten heterozygous and Pten mutant mouse models provides a new framework for 
studying in vivo the efficacy of target therapies directed against the PI3K pathway, 
as advanced metastatic tumors are often addicted to “trunkular” mutations. 
INTRODUCTION
The phosphoinositide 3-kinase (PI3K)/AKT/
mTOR network is one of the most important and well-
characterized signaling pathways involved in the 
regulation of cell growth, proliferation and survival in 
response to the presence of growth factors or specific 
hormones such as insulin [1, 2]. Upon activation of 
receptor tyrosine kinases (RTKs), PI3K is recruited in 
the plasma membrane to transform phosphatidylinositol-
4,5,-bisphosphate (PI-4,5-P2) to phosphatidylinositol-
3,4,5,-trisphosphate (PI-3,4,5-P3), which, in turn, is 
recognized and bound by proteins carrying the pleckstrin 
homology (PH) domains [2, 3]. A nodal member among 
the PH-proteins is the serine-threonine kinase AKT. Once 
activated through phosphorylation of threonine 308 and 
serine 473 by PDK1 and mTOR complex 2 (mTORC2), 
respectively, AKT may phosphorylate a large number of 
target proteins and by either inhibiting or activating them, 
regulate cell metabolism and growth (GSK3, mTORC1, 
AS160, TSC2, PRAS40), proliferation (Wee1, p21, 
p27Kip1), and apoptosis (XIAP, BAD, MDM2, Caspase 
9, FoxO1) [4]. Activation of PI3K signaling by somatic 
mutations in the PIK3CA gene has been frequently 
described in glioblastoma, breast, endometrial, colorectal, 
and hepatocellular cancers, while amplifications of the 
PIK3CA gene are common in lung, cervical, ovarian, and 
gastric cancers [5]. Oncotarget 895 www.impactjournals.com/oncotarget
By turning PI-3,4,5-P3 to PI-4,5-P2, the lipid 
phosphatase PTEN is the most important negative 
regulator of PI3K signaling activation, and one of the 
most frequently affected genes in human cancer [6, 7]. 
Dysfunctional levels of PTEN have been reported in 
the 50-80% of endometrial carcinoma, glioblastoma and 
prostate cancer, and in 30-50% of breast, colon and lung 
tumors, while germline mutations of PTEN have been 
described in a group of autosomal dominant syndromes 
collectively referred to as the PTEN hamartoma tumor 
syndromes (PHTS) [8]. 
In summary, over-activation of PI3K/AKT signaling 
is an extremely frequent event in human cancer that may 
impinge on many different aspects of tumorigenesis, 
such as cellular proliferation, resistance to apoptosis, 
angiogenesis, and metastasis [9]. 
Recently, PI3K signaling deregulation as a 
consequence of PIK3CA mutations or PTEN loss has 
been described in respectively 8% and 50% of human 
gallbladder carcinoma (GBC) [10-13]. GBC is the 
most common tumor of the biliary tract and one of the 
most frequent cancers of the gastrointestinal apparatus. 
Although relatively rare, GBC is extremely lethal with 
less than 5% of patients surviving beyond 5 years as 
most GBCs are diagnosed at an advanced stage, when 
chemotherapy has a limited impact and surgical resection 
is no longer resolutive [14]. Notably, different studies 
have described a correlation between the presence of 
polypoid lesions of the gallbladder (PLG), their size 
(larger polyps are more likely to contain foci of invasive 
cancer) and the risk of developing GBC, in turn suggesting 
that PLGs may evolve in GBC [15]. Since gallbladder 
polyps are easily detectable by ultrasonography as non-
shadowing, fixed, solid masses projecting into the lumen 
of the gallbladder [15], this fast, cost-effective and, 
most importantly, painless and non-invasive type of 
examination might pave the way for targeted preventive 
therapies based on ultrasonography screening. The 
reliability of ultrasonography in the diagnosing of PLG as 
non-neoplastic or neoplastic is extremely high for lesions 
with diameters larger than 2 centimeters, but falls short for 
less extensive lesions.
Importantly, a better understanding of the molecular 
mechanisms responsible for the neoplastic transformation 
of the gallbladder mucosal epithelium and initiation of 
GBC may provide important insights for the identification 
of effective biomarkers and targeted therapies aimed at 
preventing the lethal progression of GBC.
RESULTS
Pten+/- mice develop gallbladder tumors.
The PI3K/PTEN pathway was recently implicated 
in human gallbladder carcinoma as a consequence of 
PI3K mutations [10, 12] or PTEN loss [13]. Indeed, all 
the mutations described for the PIK3CA gene are well-
known “hot spot” sites driving the constitutive activation 
of PI3K function [16]. In order to study whether PI3K/
AKT hyperactivity results in the neoplastic transformation 
of the gallbladder epithelium, we took advantage of the 
Pten knock-out mouse model previously generated in 
our laboratory [17]. Although homozygous Pten knock-
out mice are embryonically lethal, heterozygous Pten 
littermates (Pten+/-) are viable and fertile, yet highly 
tumor prone as consequence of the PTEN haploinsufficent 
regulation of the oncogenic PI3K/AKT signaling pathway 
[6]. 
Two different cohorts of C57BL/6 Pten+/- mice were 
generated and sacrificed respectively at 6 and 12 months 
of age (n=10 per cohort). After euthanasia, gallbladders 
were extracted, fixed in 4% PFA in PBS, and embedded in 
Figure  1:  Haploinsufficient  tumor  suppressive 
function of Pten in gallbladder epithelial cells. (A) H&E 
staining showing micro, small, large and very large papillomas 
(arrowheads) in 6- and 12-month-old Pten+/- mice, respectively. 
(B) Penetrance of gallbladder papilloma in 6- and 12-month-old 
wild type and Pten+/- mice. Oncotarget 896 www.impactjournals.com/oncotarget
paraffin for histopathological and histochemical analysis. 
Age-matched wild type littermates (6-month-old, n=8; 
12-month-old, n=13) served as controls. In line with our 
hypothesis, histopathological studies on H&E sections 
revealed the presence of micro and small papillomas 
characterized by cellular pleiomorphism in 50% (5 out of 
10) of 6 month-old Pten+/- mice (Fig. 1A, upper panel), 
while the gallbladder epithelium was normal in all age-
matched wild type mice (0 out of 8) (Fig. 1B; Fig. S1). 
Strikingly, large papilloma lesions were found in 90% 
(9 out of 10) of 12-month-old Pten+/- mice, while none 
of the age-matched wild type mice showed signs of 
abnormalities in their gallbladder (0 out of 13) (Fig. 1A, 
lower panel; 1B; Fig. S1). Importantly, Pten+/- papillomas 
at 12 months of age were characterized by the papillary 
proliferation of uniform small epithelial cells arranged 
in single layers, and by the presence of a narrow stalk, 
devoid of invasive epithelial cells, that closely resembled 
human neoplastic adenomas [18]. 
Benign polyps of the human gallbladder are 
generally distinguished as non-neoplastic (e.g. cholesterol 
aggregates, inflammatory polyps, or adenomyomas), or 
neoplastic (e.g. adenomas, or leiomyomas) lesions. The 
most common benign neoplastic lesion of the gallbladder 
is the adenoma, a glandular tumor composed of cells 
resembling biliary tract epithelium, generally classified 
into papillary and non-papillary types according to 
histology. Importantly, neoplastic adenomatous polyps are 
thought to represent a form of premalignant lesion with the 
potential to progress to GBC [15, 19]. 
Dysregulated PI3K signaling drives gallbladder 
epithelial cells transformation and tumor growth.
To investigate whether Pten heterozygosity in the 
gallbladder epithelium was triggering PI3K activation, 
we next stained serial sections of gallbladder with H&E 
and phosphoS473-Akt. As shown in Figure 2A, micro-
papillomas characterizing the results from 6-month-old 
Pten+/- gallbladder were clearly positive for pS473Akt, 
evidence of the role that PI3K signaling plays during the 
first steps of neoplastic cell transformation. Importantly, 
as shown in Fig. 2B, large papillary neoplastic polyps 
in 12-month-old Pten+/- gallbladders were found to be 
still characterized by high levels of pS473Akt, while the 
epithelium of both 6- and 12-month-old wild type mice 
showed no signs of PI3K/Akt activation (Fig. 2A-B, upper 
panels; Fig. 4C). 
Overall these results suggest a fundamental role of 
PI3K/AKT in the gallbladder tumorigenesis not only by 
Figure 2: Akt hyperactivation in Pten+/- gallbladder 
tumors. (A) H&E and pSer473Akt staining on serial sections 
of gallbladder collected from 6 month-old, and (B) 12 month-old 
wild type and Pten+/- mice. Arrowheads in the first and second 
panels indicate the region of tissue magnified in the third and 
forth panels. 
Figure 3: High frequency of Ki67 positive cells in Pten+/- 
gallbladder adenomas. (A) Ki67 staining of gallbladder 
epithelium of 6 and 12 month-old wild type and Pten+/- mice. 
(B) Percentage of Ki67 positive gallbladder epithelial cells in 
the cohorts of mice described in (A). Red bars in the dot-plot 
represent mean value ± s.d.. Data were analyzed using unpaired 
t-test.  pValues<0.01  were  considered  statistically  significant 
(**p<0.01).  Oncotarget 897 www.impactjournals.com/oncotarget
promoting the initial neoplastic transformation of the 
gallbladder epithelial cells, but also by sustaining the 
growth of early lesions to large papillomas, strongly 
supporting the hypothesis of the addiction of these tumors 
to PI3K/AKT hyperactivity.  
Pten+/- gallbladder adenomas are highly 
proliferative.
 Although PI3K/AKT activity is preferentially linked 
to cell growth and survival, AKT oncogenic function has 
also been related to cell proliferation [4]. To analyze 
the proliferative index of papillomas, we stained 6- and 
12-month-old wild type and Pten+/- gallbladders for the 
proliferation marker Ki67. As shown in Figure 3A (upper 
panels), Ki67 positive nuclei were particularly enriched in 
small papilloma lesions, although the difference between 
wild type and Pten+/- gallbladder was not statistically 
significant (Fig. 3B). On the contrary, the proliferation 
index level in the 12 month-old Pten+/- papillomas was 5 
times higher than in wild type littermates (Fig. 3A lower 
panels; 3B; p=0.00018). 
Lipid phosphatase dead PtenG129E mutant mice 
develop aggressive gallbladder tumors.
The onco-suppressive role of PTEN was initially 
attributed to the inhibition of PI3K activity through its 
lipid phosphatase function, however, other important roles 
of PTEN have been discovered in the control of genomic 
stability, and the cell cycle progression over the past few 
years [20]. To understand if the neoplastic transformation 
of the gallbladder epithelium in the Pten+/- mice was 
exquisitely dependent on the hyperactivation of the PI3K/
AKT pathway, or some combination of the multiple 
tumor suppressive function of PTEN, we analyzed a 
specific cohort of knock-in mice carrying the Pten-G129E 
mutant allele in heterozygosity [21]. The G129E missense 
mutation located in the catalytic pocket of PTEN is known 
to  abolish  its  lipid  phosphatase  activity  specifically, 
without affecting any of the protein phosphatase function 
or phosphatase independent functions of this tumor 
suppressor [22]. 
We found that in our cohort of Pten+/G129E mice, 
100% of samples (n=5) developed papillomas by 6 
months of age (Fig. 4A, left and middle upper panels). 
These papillomas had progressed to very large polyps in 
all the 12-month-old Pten+/G129E mice analyzed (n=5) (Fig. 
4A, left and middle lower panels). As expected, strong 
pSer473-Akt staining and a high proliferative index (Ki67) 
Figure 4: Gallbladder tumors in PtenG129E mutant mice. 
(A) H&E staining of gallbladder extracted from 6 and 12 month-
old Pten+/G129E mice (left panels). Magnifications of the region of 
tissue indicated by the dashed square are shown in the middle 
panels. pSer473Akt staining was done on serial sections (right 
panels). Arrowheads indicate the same lesion in the two panels. 
(B) Ki67 staining of gallbladder epithelium of 6- and 12-month-
old  Pten+/G129E mice. Percentage of Ki67 positive gallbladder 
epithelial cells in the cohorts of mice described in (B) is shown 
in the graph. Red bars in the dot-plot represent mean value ± s.d.. 
(C), Western blot analysis of 12-month old gallbladders collected 
from wild type (n=3), Pten+/- (n=2), and Pten+/G129E (n=2) mice.
Figure 5: Ultrasonogram analysis. Left panels: gallbladder 
(arrow) in 12 month-old wild type (upper) and Pten+/- (lower) 
mice. Middle panels: a scheme of the ultrasonogram acquisition 
shows two black circles bounding the gallbladder of wild 
type (upper) and Pten+/- (lower) mice and in red, the dense 
mass identified by ultrasonography in the apical region of the 
Pten+/- gallbladder. Right panels: H&E of the wild type (upper) 
and  Pten+/- (lower) gallbladders analyzed by ultrasonography 
showing the large papilloma in the apical part of the Pten+/- 
gallbladder.Oncotarget 898 www.impactjournals.com/oncotarget
were identified by immunohistochemistry in the lesions of 
all the mice studied (Fig. 4A, right upper and lower panels; 
4B). Interestingly, Pten+/G129E mice displayed early polyps 
(at 6 months of age) and more aggressive gallbladder 
papillomas (Grade 2 at 12 months of age) than Pten+/- mice 
(Grade 1 at 12 months of age). Western blot analysis with 
total lysates of gallbladders from 12-month old wild type 
(n=3), Pten+/- (n=2), and Pten+/G129E (n=2) mice showed 
comparable levels of Pten in both wild type and Pten+/
G129E lysates, while the reduction in Pten levels was 
evident in the Pten+/- samples (Fig. 4C). Accordingly, we 
found higher levels of phospho-Ser473Akt in Pten+/- and   
Pten+/G129E compared to wild type samples, with the   
Pten+/G129E samples presenting the highest signal. Finally, 
in line with the previously characterized cross-talk 
between PI3K and MAPK signaling [23-25], we found a 
robust reduction in the level of phospho-Erk in both the 
Pten+/- and Pten+/G129E compared to wild type samples, with 
the Pten+/G129E samples presenting the lowest signal (Fig. 
4C). 
Collectively,  these  data  confirm  the  dominant 
negative function of mutant PtenG129E over the wild 
type Pten protein in PI3K signaling inhibition, as recently 
described by our group [21], and further support the thesis 
of PI3K/AKT signaling deregulation as a main oncogenic 
driver in the gallbladder tumorigenesis. 
In vivo detection of gallbladder tumors in Pten+/- 
mice.
Gallbladder polyps in humans are generally 
diagnosed by ultrasonography examination of the 
abdomen [14, 15]. In order to determine whether large 
papillomas in 12 month-old Pten+/- mice were detectable 
by ultrasonogram, we analyzed wild type and Pten+/- 
mice with the Vevo770 high-resolution micro-imaging 
ultrasound system (Visualsonics). Consistently, in vivo 
imaging identified gallbladder polyps only in Pten+/- mice 
(Fig. 5). Histopathological analysis confirmed the presence 
of large tumors in the gallbladders of the Pten+/- mice, as 
indicated by the ultrasonogram (Fig. 5, right panel). 
DISCUSSION
Gallbladder cancer is a lethal malignancy with 
a mean survival rate of 6 months and a 5 year survival 
rate of 5% [26]. Lethality is mainly due to the fact that 
gallbladder cancer is generally asymptomatic during 
the early phases, with its diagnosis usually occurring at 
advanced stages [26]. Although possible risk factors such 
as ethnicity, gender, age, and life style might be associated 
with gallbladder cancer development, somatic genetic 
mutations  impinging  on  specific  oncosuppressors  and 
oncogenes have been recently characterized in human 
gallbladder cancer [10-13]. Among them, mutations of the 
PIK3CA gene, known to render PI3K constitutively active, 
as well as loss of PTEN have been recently described [10, 
12, 13]. However, whether deregulated activation of the 
PI3K/AKT pathway in human gallbladder carcinogenesis 
is a key factor in the onset of the disease, or alternatively a 
late event involved in the lethal progression of the tumor, 
is not yet understood [27]. Overall, our results demonstrate 
a clear role for PI3K/AKT pathway deregulation in 
gallbladder epithelial cell transformation as well as, 
importantly, in tumor growth. The papillomas observed 
in 12 month-old Pten+/- gallbladders are extensive lesions 
that frequently occupy 30%-50% of the entire organ, and 
are characterized by a high proliferative index, attributes 
that when associated with human gallbladder polyps 
generally indicate a high risk of malignant transformation. 
Importantly, the persistence of high levels of active Akt 
during onset and growth of these papillomas suggests 
the addiction of these lesions to the oncogenic PI3K/
AKT signaling. These data strongly argue for the genetic 
stratification of advanced human gallbladder carcinomas 
based on PI3K or PTEN mutations and their treatment 
with small molecule pathway inhibitors. The Pten+/- 
mouse model may therefore represent an ideal platform for 
testing both pre- and co-clinically [28, 29], the efficacy of 
drugs designed to inhibit the PI3K pathway either as single 
drug agents or in combination with standard-of-care radio- 
or chemotherapy for the treatment of human gallbladder 
carcinoma. 
METHODS
Ethics statement 
All mouse work was done in accordance with our 
IACUC protocol. 
Pten+/-, Pten+/G129E mutant mice 
Pten+/- and Pten+/G129E (C57BL/6) mice were 
generated as previously described [17, 21]. Pten+/-,   
Pten+/G129E, and wild type cohorts were generated by 
crossing Pten+/- or Pten+/G129E with wild type mice. 
Immunohistochemistry 
For immunohistochemistry, gallbladders were fixed 
in 4% formaldehyde in PBS overnight, washed once with 
PBS, and dehydrated with 25%, 50%, and 70% ethanol. 
Gallbladders were embedded in paraffin, sectioned and 
stained with hematoxylin and eosin (H&E) in accordance 
with standard procedures. For immunohistochemistry 
(IHC),  tissues  were  fixed  in  4%  formaldehyde  and 
embedded  in  paraffin  in  accordance  with  standard Oncotarget 899 www.impactjournals.com/oncotarget
procedures. Sections were stained for pSer473AKT (rabbit 
polyclonal 9271S, Cell Signaling Technology; 1:1:250), 
Ki67 (rabbit polyclonal, Novacastra; 1:400). Proliferative 
cells were identified by positive Ki-67 nuclear staining.
Western blot
For Western blot, cell and tissue lysates were 
prepared with 150-RIPA buffer and protease and 
phosphatase inhibitor cocktails (Roche). The following 
antibodies were used for Western blotting: rabbit 
polyclonal anti-PTEN (138G6; 1:1000, Cell Signaling 
Technology), rabbit polyclonal anti-phospho-Akt(S473) 
(9271S; 1:1000, Cell Signaling Technology), rabbit 
polyclonal anti-Akt (9272S; 1:1000, Cell Signaling 
Technology), rabbit polyclonal anti-GAPDH (14C10; 
1:6000, Cell Signaling Technology), rabbit polyclonal 
anti-p44/42 MAPK (Erk1/2) (9102S; 1:3000, Cell 
Signaling), rabbit polyclonal anti-Phospho-p44/42 
MAPK (Erk1/2) (Thr202/Tyr204) (9101S; 1:3000, Cell 
Signaling).
Imaging of gallbladder lesions
High-resolution ultrasound (US) imaging of normal 
and diseased mouse gallbladders was carried out using the 
Vevo 2100 System (Visual Sonics, Inc.).  Briefly, mice 
were anesthetized with a 3% isoflurane/oxygen mixture 
and subsequently transferred to a platform heated to 
39/40°C. Abdominal hair was removed by shaving and 
subsequent application of depilatory cream, followed by 
ample washing with sterile water to prevent irritation to 
the skin.  Ultrasound gel was applied to the abdominal 
area of the mice and scanning performed with a with a 
32–56 MHz MircoscanTM transducer (MS-550S, Visual 
Sonics, Inc).  Upon completion of imaging mice were 
returned to their cage and observed until fully recovered 
anesthesia.
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